Historical profiles of Mayo Clinic: The 1950 Novel Prize in Physiology or Medicine

From: Mayo Clinic Proceedings | Date: December 1, 2000| Author: Lantz, Jane C | Copyright information

On December 10, 1950, two Mayo Clinic staff members were awarded the Nobel Prize in physiology or medicine. They were researcher Edward Calvin Kendall, PhD, DSc (1886-1972), and clinician Philip Showalter Hench, MD, ScD (1896-1965). In addition, for work that paralleled and complemented that of Dr Kendall and Dr Hench, Tadeus Reichstein, PhD (1897-1996), of Basel, Switzerland, shared the award.

In the presentation speech, Professor G. Liljestrand, of the Royal Caroline Institute, said...

Read all of this article with a FREE trial to HighBeam Research

Related newspaper, magazine, and journal articles from HighBeam Research

MANAGEMENT OF RHEUMATOID ARTHRITIS.(TRIAD)
The News & Record (Piedmont Triad, NC) ; Byline: Robert M. Gay< Special to the News & Record Rheumatoid arthritis (RA) is a relatively common disease in which the lining or membranes of joints become inflamed ...
Quality of Life in American Indian and White Women With and Without Rheumatoid Arthritis
The American Journal of Occupational Therapy ; OBJECTIVE. The purpose of this study was to examine quality of life (QOL) in American Indian and White women with and without rheumatoid arthritis. METHOD. This cross-sectional study included 64 women in four groups: American Indians with rheumatoid arthritis, healthy American Indians, Whites with
Rheumatoid arthritis medication may extend life while easing pain
The Milwaukee Journal Sentinel ; Rheumatoid arthritis medication may extend life while easing pain By EMMA ROSS Associated Press Monday, April 15, 2002 London -- Methotrexate, a key drug for rheumatoid arthritis, could help people with the crippling disease live longer, new research suggests. Methotrexate, originally a cancer
Most Sjorgen's patients negative for RA antibodies.(Musculoskeletal Disorders)(rheumatoid arthritis)
Family Practice News ; Most patients with primary Sjorgen's syndrome test negative for anti-cyclic citrullinated peptide antibody and antikeratin antibodies, in contrast to patients with rheumatoid arthritis, a new study shows. However, primary Sjorgen's syndrome should not be ruled out in patients testing positive for
Anti-TNF therapy in early rheumatoid arthritis.(tumor necrosis factor)(Clinical report)
Bandolier ; Anti-TNF therapy for rheumatoid arthritis has a proven high degree of effectiveness (Bandolier 99) in clinical trials and the real world (Bandolier 104). In the main all these patients were already using disease-modifying drugs, or had failed to improve on them. Two new studies [1,2] suggest that